A Phase III open-label, randomized, multicenter study of imprime pgg in combination with cetuximab in patients with kras wild type metastatic colorectal cancer
Meyerhardt, Jeffrey A, Grady, Michele M, Lowe, Jamie N, Gargano, Michele A, Huhn, Richard D, Braun, Ada H
Published in Journal for immunotherapy of cancer (06.11.2014)
Published in Journal for immunotherapy of cancer (06.11.2014)
Get full text
Journal Article
ARC-6: A phase 1b/2, open-label, randomized platform study to evaluate efficacy and safety of etrumadenant (AB928)-based treatment combinations in patients with metastatic castrate-resistant prostate cancer (mCRPC)
Subudhi, Sumit Kumar, Bendell, Johanna C., Carducci, Michael Anthony, Kopp, Lisa M., Scott, Jennifer, Grady, Michele M, Gardner, Olivia, Wise, David R
Published in Journal of clinical oncology (20.05.2021)
Published in Journal of clinical oncology (20.05.2021)
Get full text
Journal Article
A phase 3 open-label, randomized, multicenter study of imprime PGG in combination with cetuximab in patients with KRAS wild type metastatic colorectal cancer
Huhn, Richard Dale, Lowe, Jamie, Grady, Michele M, Taitt, Corina Candiani, Braun, Ada H.
Published in Journal of clinical oncology (20.05.2015)
Published in Journal of clinical oncology (20.05.2015)
Get full text
Journal Article
A phase 3 open-label, randomized, multicenter study of Imprime PGG in combination with cetuximab in patients with KRAS wild type metastatic colorectal cancer
Huhn, Richard Dale, Lowe, Jamie, Grady, Michele, Taitt, Corina Candiani, Gargano, Michele Anne, Braun, Ada H.
Published in Journal of clinical oncology (20.01.2015)
Published in Journal of clinical oncology (20.01.2015)
Get full text
Journal Article